Using genetic and neuroimaging correlates of early psychosis to investigate the underlying mechanisms of the disorder.
Lead Research Organisation:
King's College London
Department Name: Developmental Neurobiology
Abstract
The aim of this project is to find genetic and neuroimaging predictors of treatment response both to antipsychotic medication (Aim 1) and to cannabidiol (Aim 2) in patients with first episode psychosis. By recruiting first episode patients we hope to find predictors of treatment response in early stages of the disorder. Resistance to antipsychotic medication is associated with both genetic and brain metric differences (Vita et al. 2019). I will test the hypothesis that these factors also influence the response to antipsychotics and to cannabidiol.
| Description | OPTIMISE proteomic data |
| Organisation | University of Dublin |
| Country | Ireland |
| Sector | Academic/University |
| PI Contribution | Worked together to analyse proteomic data |
| Collaborator Contribution | The proteomic analysis expertise |
| Impact | Paper: Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial. |
| Start Year | 2021 |